HIF2α Inhibitor clinical trials at UCLA

1 in progress, 0 open to eligible people

NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma
Sorry, in progress, not accepting new patients
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Los Angeles, California and other locations

Last updated: October 14, 2024